SC
AVIR icon

Shay Capital’s Atea Pharmaceuticals AVIR Stock Holding History

Shay Capital’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,466
Closed -$42K – 495
2025
Q3 		$42K Sell
14,466
-18,488
-56% -$63.1K ﹤0.01% 398
2025
Q2 		$119K Sell
32,954
-28,170
-46% -$84K 0.01% 275
2025
Q1 		$183K Buy
61,124
+30,491
+100% +$95.2K 0.03% 243
2024
Q4 		$103K Buy
30,633
+12,871
+72% +$42.8K 0.02% 277
2024
Q3 		$59.5K Sell
17,762
-6,424
-27% -$23.3K 0.01% 287
2024
Q2 		$80.1K Buy
24,186
+6,020
+33% +$22.4K 0.01% 246
2024
Q1 		$73.4K Sell
18,166
-31,973
-64% -$125K 0.01% 337
2023
Q4 		$153K Buy
50,139
+1,504
+3% +$4.55K 0.03% 215
2023
Q3 		$146K Buy
48,635
+14,000
+40% +$47.6K 0.02% 272
2023
Q2 		$130K Buy
+34,635
New +$130K 0.02% 318

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Shay Capital's AVIR Position: Q4 2025 in Review

Shay Capital sold out of Atea Pharmaceuticals (AVIR) in Q4 2025, closing a stake of 14,466 shares — an estimated $42K sold.

Shay Capital first reported a position in AVIR in Q2 2023 and held it in 10 quarters. The position peaked at $183K in Q1 2025. 111 funds tracked by Wall St. Rank hold AVIR as of Q4 2025.

  • Shay Capital reported no remaining Atea Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Shay Capital sold 14,466 Atea Pharmaceuticals shares in Q4 2025, an estimated $42K.
  • Shay Capital first reported a position in Atea Pharmaceuticals in Q2 2023 and held it in 10 quarters.
  • Shay Capital's Atea Pharmaceuticals position peaked at $183K in Q1 2025.
  • 111 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2025.

Based on Shay Capital's 13F filing for Q4 2025, filed 17 Feb 2026.